Photo by Towfiqu barbhuiya
Geneva — September 24, 2025 – A landmark global agreement has been reached to make injectable HIV prevention treatments more affordable and accessible, marking a major step forward in the fight against the epidemic.
The deal, announced by health agencies and pharmaceutical partners, will significantly reduce the cost of long-acting injectable drugs used as pre-exposure prophylaxis (PrEP), making them available to millions in low- and middle-income countries where access has been limited by high prices.
Health experts say the new arrangement could transform HIV prevention strategies by offering a discreet and effective alternative to daily pills. The injectable jab, administered once every two months, has been shown to reduce the risk of HIV infection by more than 90 percent when used consistently.
“This is a game-changer,” said a spokesperson from UNAIDS. “Affordable access to long-acting HIV prevention will save countless lives and bring us closer to ending the epidemic.”
Until now, limited supply chains and high costs have meant the jab was largely accessible only in wealthier nations. Under the new deal, international organizations will partner with manufacturers to scale up production, accelerate regulatory approvals, and expand distribution to vulnerable communities worldwide.
Global health advocates welcomed the announcement but stressed the need for swift implementation. “It’s not just about lowering the price — it’s about ensuring the jab reaches those who need it most,” said one campaigner.
The agreement is being hailed as a critical milestone in global public health, with the potential to reshape HIV prevention efforts and reduce new infections dramatically in the years ahead.
About the Author
